ODAC 30% Off Registration, Use Code: JDD30
Skip to main content
Featured ArticlesJDD HighlightsLatest News

Impetigo Antibiotic Stewardship and the Need for Treatment Alternatives

By November 17, 2026No Comments

Rethinking Impetigo Management: Why Antimicrobial Stewardship Matters Now in Dermatology

This is a must-read consensus review from the Journal of Drugs in Dermatology examining how rising antimicrobial resistance is reshaping the treatment of localized impetigo. For practicing dermatologists, pediatric dermatologists, and dermatology healthcare professionals, the clinical landscape around topical antibiotics requires fresh attention.


While topical antibiotics remain first-line therapy for uncomplicated impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, widespread resistance to standard agents like mupirocin, fusidic acid, and retapamulin is creating real challenges in daily practice. Treating impetigo promptly is essential to reduce symptoms, limit transmission, and prevent complications, yet relying on legacy therapies without accounting for local resistance trends can undermine patient outcomes.

To address these clinical gaps, an international panel of dermatology and pediatric experts convened in February 2026 to evaluate current treatment efficacy, safety, and resistance patterns. Their review underscores that impetigo management represents a vital opportunity for antimicrobial stewardship in dermatology, emphasizing the right agent for the right duration alongside novel options like topical ozenoxacin and antibiotic-sparing strategies.

How can you best integrate stewardship principles into your prescribing habits, and where do newer topical agents fit into your clinical algorithm? Click through to read the full JDD article for the panel’s complete clinical insights and evidence-based strategies to optimize impetigo care in your practice.

Blog write-up assisted by AI